BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31124415)

  • 1. Genomic profiling and predicting treatment response in acute myeloid leukemia.
    Isidori A; Loscocco F; Curti A; Amadori S; Visani G
    Pharmacogenomics; 2019 May; 20(7):467-470. PubMed ID: 31124415
    [No Abstract]   [Full Text] [Related]  

  • 2. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia.
    Levine RL; Valk PJM
    Haematologica; 2019 May; 104(5):868-871. PubMed ID: 30923100
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
    Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
    Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms.
    Kuo FC
    Surg Pathol Clin; 2016 Sep; 9(3):475-88. PubMed ID: 27523973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of recurrent, rare, and novel gene fusions in patients with acute leukemia using next-generation sequencing approaches.
    Kim B; Kim E; Lee ST; Cheong JW; Lyu CJ; Min YH; Choi JR
    Hematol Oncol; 2020 Feb; 38(1):82-88. PubMed ID: 31875988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia.
    Niu P; Yao B; Wei L; Zhu H; Fang C; Zhao Y
    Blood Cells Mol Dis; 2019 Jul; 77():43-50. PubMed ID: 30954792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification.
    de Noronha TR; Mitne-Neto M; Chauffaille ML
    J Investig Med; 2017 Dec; 65(8):1155-1158. PubMed ID: 28923882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chordoma of the Clivus and Acute Myeloid Leukemia: Is There a Connection?
    Larkin T; Macak R; Lagmay J; Horn B
    J Pediatr Hematol Oncol; 2020 Oct; 42(7):e662-e664. PubMed ID: 31764514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Precision medicine for acute myeloid leukemia based on genomic profiling].
    Sanada M
    Rinsho Ketsueki; 2019; 60(7):847-853. PubMed ID: 31391376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis.
    Weber S; Haferlach T; Haferlach C; Kern W
    Blood Cancer J; 2016 Dec; 6(12):e507. PubMed ID: 27935581
    [No Abstract]   [Full Text] [Related]  

  • 12. Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
    Rapaport F; Neelamraju Y; Baslan T; Hassane D; Gruszczynska A; Robert de Massy M; Farnoud N; Haddox S; Lee T; Medina-Martinez J; Sheridan C; Thurmond A; Becker M; Bekiranov S; Carroll M; Moses Murdock H; Valk PJM; Bullinger L; D'Andrea R; Lowe SW; Neuberg D; Levine RL; Melnick A; Garrett-Bakelman FE
    Leukemia; 2021 Sep; 35(9):2688-2692. PubMed ID: 33580203
    [No Abstract]   [Full Text] [Related]  

  • 13. Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease.
    Marjanovic I; Kostic J; Stanic B; Pejanovic N; Lucic B; Karan-Djurasevic T; Janic D; Dokmanovic L; Jankovic S; Vukovic NS; Tomin D; Perisic O; Rakocevic G; Popovic M; Pavlovic S; Tosic N
    Tumour Biol; 2016 Oct; 37(10):13391-13401. PubMed ID: 27460089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia.
    Wang SY; Chen WL; Wang ZC; Li XF; Lin SL; Gao C; Huang YM; Luo DF; Li JG; Zi YM; Yi Z; Lin Y; Lai L; Pan LL
    Leuk Lymphoma; 2016 Nov; 57(11):2727-30. PubMed ID: 27064024
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular characterization of acute myeloid leukemia and its impact on treatment.
    Frankfurt O; Licht JD; Tallman MS
    Curr Opin Oncol; 2007 Nov; 19(6):635-49. PubMed ID: 17906465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic hallmarks in AML.
    Clarke MA; Fisher J
    Nat Biomed Eng; 2019 Nov; 3(11):847-849. PubMed ID: 31705121
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
    Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
    J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics.
    Copelan EA; Grunwald MR; Druhan LJ; Avalos BR
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):143-9. PubMed ID: 26459077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy.
    Frattini MG; Maslak PG
    J Natl Compr Canc Netw; 2008 Nov; 6(10):995-1002. PubMed ID: 19176197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.